North America Sarcopenia Treatment Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2024 –2030 |
 Market Size (Base Year) |
|
 Market Size (Forecast Year) |
USD 1,814,892.90 |
 CAGR |
% |
| Major Markets Players |
>北美肌肉减少症治疗市场，按治疗类型（药物、维生素/膳食补充剂等）、类型（原发性肌肉减少症和继发性肌肉减少症）、阶段（前期肌肉减少症、肌肉减少症和重度肌肉减少症）、给药途径（口服、注射等）、性别（男性和女性）、最终用户（医院、专科诊所、家庭医疗保健等）、分销渠道（直接招标、零售销售等）– 行业趋势和预测到 2030 年。
北美肌肉减少症治疗市场分析和规模
推动北美肌肉减少症治疗市场增长的主要因素是肌肉减少症患病率的上升。此外，人们对肌肉减少症及其对健康的不利影响的认识不断提高是推动市场增长的另一个关键因素。营养不良和久坐不动等生活方式因素也会影响市场。然而，缺乏标准化诊断以及治疗和干预的高成本预计将抑制市场增长。
Data Bridge Market Research 分析，北美肌肉减少症治疗市场预计到 2030 年将达到 1,814,892.90 万美元的价值，预测期内的复合年增长率为 5.0%。本市场报告还深入介绍了定价分析和技术进步。
|
报告指标 |
细节 |
|
预测期 |
2023 至 2030 年 |
|
基准年 |
2022 |
|
历史岁月 |
2021（可定制为 2015 - 2020） |
|
定量单位 |
收入（千美元）、销量（单位）、定价（美元） |
|
涵盖的领域 |
治疗类型（药物、维生素/膳食补充剂等）、类型（原发性肌肉减少症和继发性肌肉减少症）、阶段（前期肌肉减少症、肌肉减少症和重度肌肉减少症）、给药途径（口服、注射等）、性别（男性和女性）、最终用户（医院、专科诊所、家庭医疗保健等）、分销渠道（直接招标、零售等） |
|
覆盖国家 |
美国、加拿大和墨西哥 |
|
涵盖的市场参与者 |
雅培、雀巢健康科学（雀巢公司的子公司）、诺华公司、赛诺菲、Haleon 集团、巴斯夫 SE、Bio Thrive Sciences、帝斯曼、Fermenta Biotech Limited、AstaReal Co., Ltd.、Metagenics、Wellona Pharma、The Vitamin Company India、Healing Pharma India Pvt. Ltd. 等 |
市场定义
肌肉减少症治疗是指与旨在预防、控制或治疗肌肉减少症的产品和服务相关的商业领域。肌肉减少症是一种与年龄有关的进行性疾病，其特征是骨骼肌质量、力量和功能的丧失，通常始于 30 岁左右，并在 60 岁后加速。
肌肉减少症对个人的整体健康和生活质量有重大影响。肌肉力量和耐力会相应下降，使日常任务更具挑战性，并且随着肌肉质量的下降，跌倒和骨折的风险也会增加。此外，肌肉减少症还会导致代谢变化、胰岛素抵抗和肥胖可能性增加。
北美肌肉减少症治疗市场动态
本节旨在了解市场驱动因素、优势、机遇、限制和挑战。下面将详细讨论所有这些内容：
驱动程序
- 肌肉减少症患病率上升
肌肉减少症是一种以肌肉质量、力量和功能下降为特征的疾病，尤其发生在老年人身上。随着年龄的增长，老年人的肌肉质量和功能会逐渐下降，这导致他们容易患上肌肉减少症。随着世界人口老龄化，患上肌肉减少症的人数正在稳步增加。这种人口结构的变化直接推动了对肌肉减少症治疗方案的需求。该病的患病率不断上升意味着需要诊断和治疗的人数越来越多，从而为肌肉减少症治疗市场创造了更大的患者群体。
随着医疗保健和医学的进步，人们的寿命越来越长。然而，随着年龄的增长，人们患上肌肉减少症的可能性也越来越大。这种较长的预期寿命导致该病的总体患病率上升。糖尿病、心血管疾病和癌症等慢性疾病会导致肌肉损失并导致肌肉减少症的发生。这些疾病发病率的上升直接影响了肌肉减少症患病率的上升。
随着世界人口不断老龄化，对预防或控制肌肉减少症的有效干预措施的需求预计将增加，从而促进肌肉减少症治疗领域的研究、开发和创新，预计这将推动市场增长。
- 人们对肌肉减少症及其对健康的有害影响的认识不断提高
人们对肌肉减少症及其对健康的有害影响的认识不断提高，这是医疗保健和老龄化领域的重大发展。与肌肉减少症相关的研究和出版物显著增加。科学研究、医学期刊和出版物为医疗保健专业人员提供了有关该病的患病率、诊断和后果的宝贵信息。医学院和培训项目已将肌肉减少症纳入课程。这确保医疗保健专业人员（包括医生、护士和理疗师）接受有关肌肉减少症、其风险因素和管理策略的教育。
各种倡导团体和组织一直在积极提高人们对肌肉减少症的认识。这些团体经常与医疗保健专业人员合作，向公众宣传这种疾病的风险以及早期诊断和干预的重要性。肌肉减少症在主流媒体中得到了越来越多的报道，包括文章、新闻报道和纪录片。这种曝光有助于提高公众的认识。
因此，对肌肉减少症认识的提高将成为肌肉减少症治疗市场增长的催化剂，因为它可以提高早期诊断率、增加患者需求、增加研究资金以及开发创新解决方案。随着对肌肉减少症的认识不断加深，肌肉减少症预防和管理市场可能会进一步扩大，这有望推动市场增长。
机会
- 市场参与者的战略举措
肌肉减少症治疗市场正在经历大幅增长，因为它是一种与年龄有关的渐进性疾病，其特征是肌肉质量、力量和功能的丧失。这是一个重大的健康问题，尤其是对老年人来说，因为它会导致行动能力下降、跌倒和骨折风险增加以及整体生活质量下降，因此主要市场参与者正在积极采取战略举措进行产品开发。从而为市场扩张和发展开辟了机会。
战略计划包括与研究机构、医疗保健组织和学术中心的合作和伙伴关系。市场参与者可以利用他们的知识和资源，通过与该领域的专家合作来加速肌肉减少症治疗的开发和商业化。此类合作促进了知识交流、接触临床试验患者群体以及汇集专业知识以推动市场创新。
此外，市场参与者正积极进行战略收购和合并，以扩大其产品组合并加强其市场占有率。这些战略举措使公司能够获得更广泛的治疗选择和技术，从而为肌肉减少症管理提供全面的解决方案。
市场参与者也在投资营销和宣传活动，以教育医疗保健专业人员和公众了解肌肉减少症。市场参与者可以通过提高人们对该病症、其后果和可用治疗方案的认识来推动对肌肉减少症治疗的需求。随着越来越多的人寻求肌肉减少症的诊断和治疗，这为市场增长创造了机会。因此，上述情况表明，主要市场参与者的战略举措正在成为市场增长的机会。
克制/挑战
- 缺乏标准化诊断
缺乏标准化诊断标准可能会导致延迟诊断或漏诊肌肉减少症病例。医疗保健专业人员可能不会定期筛查该疾病，尤其是成年人，这可能会妨碍早期干预和治疗。如果没有标准化诊断，医疗保健提供者可能会使用不同的标准和方法来识别肌肉减少症。这种不一致可能导致报告的肌肉减少症患病率和确诊病例数存在差异，这使得评估真正的市场规模和治疗需求变得具有挑战性。
肌肉减少症是一种多方面的疾病，会根据年龄、性别和合并症等因素对个体产生不同的影响。患者群体可能各不相同，因此，如果没有标准化的诊断标准，就很难进行临床试验和研究以准确评估治疗效果。肌肉减少症治疗的临床试验可能使用不同的诊断标准，因此很难比较不同研究的结果。这种标准化的缺乏可能会阻碍监管机构开发和批准新的治疗方法。
因此，缺乏对肌肉减少症的标准化诊断会导致病情的评估、治疗和研究出现不一致和挑战，预计这会抑制市场增长。
北美肌肉减少症治疗市场范围
北美肌肉减少症治疗市场分为七个显著的细分市场，例如治疗类型、类型、阶段、给药途径、性别、最终用户和分销渠道。这些细分市场之间的增长将帮助您分析行业中增长微弱的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。
治疗类型
- 维生素/膳食补充剂
- 药物
- 其他的
根据治疗类型，市场分为药物、维生素/膳食补充剂和其他。
类型
- 原发性肌肉减少症
- 继发性肌肉减少症
根据类型，市场分为原发性肌肉减少症和继发性肌肉减少症。
阶段
- 肌肉减少症前期
- 肌肉减少症
- 严重肌肉减少症
根据阶段，市场分为肌少症前期、肌少症和重度肌少症。
给药途径
- 口服
- 注射剂
- 其他的
根据给药途径，市场分为口服、注射和其他。
性别
- 男性
- 女性
根据性别，市场分为男性和女性。
最终用户
- 医院
- 专科诊所
- 家庭医疗保健
- 其他的
根据最终用户，市场分为医院、专科诊所、家庭医疗保健和其他。
分销渠道
- 直接招标
- 零售销售
- 其他的
根据分销渠道，市场分为直接招标、零售销售和其他。
北美肌肉减少症治疗市场区域分析/见解
北美肌肉减少症治疗市场分为七个显著部分，例如治疗类型、类型、阶段、给药途径、性别、最终用户和分销渠道。
本市场报告涵盖的国家包括美国、加拿大和墨西哥。
由于各制造商的投资水平较高且该地区对药品制造的需求不断增加，美国在北美肌肉减少症治疗市场占据主导地位。
报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和市场监管变化。下游和上游价值链分析、技术趋势、波特五力分析和案例研究等数据点是用于预测各个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了欧洲品牌的存在和可用性以及由于来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税的影响和贸易路线。
竞争格局和北美肌肉减少症治疗市场份额分析
北美肌肉减少症治疗市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度以及应用主导地位。以上提供的数据点仅与公司对市场的关注有关。
北美肌肉减少症治疗市场的一些主要市场参与者包括雅培、雀巢健康科学（雀巢公司的子公司）、诺华公司、赛诺菲、海利昂集团、巴斯夫欧洲公司、Bio Thrive Sciences、帝斯曼、Fermenta Biotech Limited、AstaReal Co., Ltd.、Metagenics、Wellona Pharma、The Vitamin Company India、Healing Pharma India Pvt. Ltd. 等。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA SARCOPENIA TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 TREATMENT TYPE SEGMENT LIFELINE CURVE
2.8 MARKET END USER COVERAGE GRID
2.9 DBMR MARKET POSITION GRID
2.1 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 NORTH AMERICA SARCOPENIA TREATMENT MARKET: REGULATIONS
5.1 REGULATIONS IN THE U.S.
5.2 REGULATIONS IN CANADA
5.3 REGULATIONS IN MEXICO
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING PREVALENCE OF SARCOPENIA
6.1.2 GROWING AWARENESS OF SARCOPENIA AND ITS DETRIMENTAL EFFECTS ON HEALTH
6.1.3 LIFESTYLE FACTORS SUCH AS POOR NUTRITION AND SEDENTARY BEHAVIOUR
6.2 RESTRAINTS
6.2.1 LACK OF STANDARDIZED DIAGNOSIS
6.2.2 HIGH COST OF TREATMENT AND INTERVENTIONS
6.3 OPPORTUNITIES
6.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS
6.3.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES
6.4 CHALLENGES
6.4.1 COMPLICATIONS ASSOCIATED WITH THE SARCOPENIA TREATMENT
6.4.2 STRINGENT GOVERNMENT RULES AND REGULATION FOR PRODUCT APPROVAL
7 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE
7.1 OVERVIEW
7.2 VITAMIN/DIETARY SUPPLEMENTS
7.2.1 VITAMIN SUPPLEMENTS
7.2.2 PROTEIN SUPPLEMENTS
7.2.3 FATTY ACID SUPPLEMENTS
7.2.4 CREATINE
7.2.5 WHEY PROTEINS
7.2.6 L-CARNITINE
7.2.7 SOY
7.2.8 BETA-ALANINE
7.2.9 OSTARINE
7.2.10 COLLAGEN PEPTIDES
7.2.11 LIGANDROL
7.2.12 BRANCH-CHAIN AMINO ACIDS
7.2.13 HYDROXYMETHYLBUTYRATE (HMB)
7.2.14 MEDIUM CHAIN TRIGLYCERIDES
7.2.15 OTHERS
7.3 MEDICATIONS
7.3.1 OFF LABEL DRUGS
7.3.2 EMERGING DRUGS
7.3.2.1 ACE INHIBITORS
7.3.2.2 APPETITE STIMULANTS
7.3.2.3 ORAL ANTIDIABETIC DRUGS
7.3.2.4 OTHERS
7.4 OTHERS
8 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY TYPE
8.1 OVERVIEW
8.2 PRIMARY SARCOPENIA
8.2.1 VITAMIN/DIETARY SUPPLEMENTS
8.2.2 MEDICATIONS
8.2.3 OTHERS
8.3 SECONDARY SARCOPENIA
8.3.1 VITAMIN/DIETARY SUPPLEMENTS
8.3.2 MEDICATIONS
8.3.3 OTHERS
9 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY STAGES
9.1 OVERVIEW
9.2 PRE-SARCOPENIA
9.3 SARCOPENIA
9.4 SEVERE SARCOPENIA
10 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
10.1 OVERVIEW
10.2 ORAL
10.3 INJECTABLES
10.4 OTHERS
11 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY GENDER
11.1 OVERVIEW
11.2 MALE
11.3 FEMALE
12 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITALS
12.2.1 PUBLIC
12.2.2 PRIVATE
12.3 SPECIALTY CLINICS
12.4 HOME HEALTHCARE
12.5 OTHERS
13 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDER
13.3 RETAIL SALES
13.3.1 HOSPITAL PHARMACIES
13.3.2 ONLINE PHARMACIES
13.3.3 OTHERS
13.4 OTHERS
14 NORTH AMERICA SARCOPENIA TREATMENT MARKET BY COUNTRY
14.1 NORTH AMERICA
14.1.1 U.S.
14.1.2 CANADA
14.1.3 MEXICO
15 NORTH AMERICA SARCOPENIA TREATMENT MARKET, COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 ABBOTT
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 PRODUCT PORTFOLIO
17.1.4 RECENT DEVELOPMENT
17.2 NESTLÉ HEALTH SCIENCE (A SUBSIDIARY OF NESTLÉ S.A.)
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 PRODUCT PORTFOLIO
17.2.4 RECENT DEVELOPMENT
17.3 NOVARTIS AG
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 PRODUCT PORTFOLIO
17.3.4 PIPELINE PORTFOLIO
17.3.5 RECENT DEVELOPMENT
17.4 SANOFI
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.5 PRODUCT PORTFOLIO
17.5.1 RECENT DEVELOPMENT
17.6 HALEON GROUP OF COMPANIES.
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENT
17.7 ASTAREAL CO., LTD.
17.7.1 COMPANY SNAPSHOT
17.7.2 PRODUCT PORTFOLIO
17.7.3 RECENT DEVELOPMENT
17.8 BASF SE
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT DEVELOPMENT
17.9 BIOTHRIVE SCIENCES
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENT
17.1 DSM
17.10.1 COMPANY SNAPSHOT
17.10.2 REVENUE ANALYSIS
17.10.3 PRODUCT PORTFOLIO
17.10.4 RECENT DEVELOPMENT
17.11 FERMENTA BIOTECH LIMITED
17.11.1 COMPANY SNAPSHOT
17.11.2 REVENUE ANALYSIS
17.11.3 PRODUCT PORTFOLIO
17.11.4 RECENT DEVELOPMENT
17.12 HEALING PHARMA INDIA PVT.IND.
17.12.1 COMPANY SNAPSHOT
17.12.2 PRODUCT PORTFOLIO
17.12.3 RECENT DEVELOPMENT
17.13 METAGENICS
17.13.1 COMPANY SNAPSHOT
17.13.2 PRODUCT PORTFOLIO
17.13.3 RECENT DEVELOPMENT
17.14 THE VITAMIN COMPANY INDIA
17.14.1 COMPANY SNAPSHOT
17.14.2 PRODUCT PORTFOLIO
17.14.3 RECENT DEVELOPMENT
17.15 WELLONA PHARMA
17.15.1 COMPANY SNAPSHOT
17.15.2 PRODUCT PORTFOLIO
17.15.3 RECENT DEVELOPMENT
17.16 ARMGO PHARMA, INC.
17.16.1 COMPANY SNAPSHOT
17.16.2 PIPELINE PORTFOLIO
17.16.3 RECENT DEVELOPMENT
17.17 BIOPHYTIS
17.17.1 COMPANY SNAPSHOT
17.17.2 PIPELINE PORTFOLIO
17.17.3 RECENT DEVELOPMENT
17.18 DYSTROGEN THERAPEUTICS CORP
17.18.1 COMPANY SNAPSHOT
17.18.2 PIPELINE PORTFOLIO
17.18.3 RECENT DEVELOPMENT
17.19 MYMD PHARMACEUTICALS
17.19.1 COMPANY SNAPSHOT
17.19.2 PIPELINE PORTFOLIO
17.19.3 RECENT DEVELOPMENT
17.2 OPKO HEALTH, INC.
17.20.1 COMPANY SNAPSHOT
17.20.2 REVENUE ANALYSIS
17.20.3 PIPELINE PORTFOLIO
17.20.4 RECENT DEVELOPMENT
17.21 REGENERON PHARMACEUTICALS INC.
17.21.1 COMPANY SNAPSHOT
17.21.2 REVENUE ANALYSIS
17.21.3 PIPELINE PORTFOLIO
17.21.4 RECENT DEVELOPMENT
18 QUESTIONNAIRE
19 RELATED REPORTS
表格列表
TABLE 1 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 2 NORTH AMERICA VITAMIN/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 3 NORTH AMERICA MEDICATINONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 4 NORTH AMERICA OFF-LABLE DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 5 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 6 NORTH AMERICA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 7 NORTH AMERICA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 8 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 9 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 10 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 11 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 12 NORTH AMERICA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 13 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 14 NORTH AMERICA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 15 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)
TABLE 16 U.S. SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 17 U.S. MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 18 U.S. OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 19 U.S. OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 20 U.S. OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 21 U.S. VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 22 U.S. SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 23 U.S. PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 24 U.S. SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 25 U.S. SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 26 U.S. SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 27 U.S. SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 28 U.S. SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 29 U.S. HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 30 U.S. SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 31 U.S. RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 32 CANADA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 33 CANADA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 34 CANADA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 35 CANADA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 36 CANADA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 37 CANADA VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 38 CANADA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 39 CANADA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 40 CANADA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 41 CANADA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 42 CANADA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 43 CANADA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 44 CANADA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 45 CANADA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 46 CANADA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 47 CANADA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 48 MEXICO SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 49 MEXICO MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 50 MEXICO OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 51 MEXICO OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 52 MEXICO OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 53 MEXICO VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 54 MEXICO SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 55 MEXICO PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 56 MEXICO SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 57 MEXICO SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 58 MEXICO SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 59 MEXICO SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 60 MEXICO SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 61 MEXICO HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 62 MEXICO SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 63 MEXICO RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
图片列表
FIGURE 1 NORTH AMERICA SARCOPENIA TREATMENT MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA SARCOPENIA TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA SARCOPENIA TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA SARCOPENIA TREATMENT MARKET: REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA SARCOPENIA TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA SARCOPENIA TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA SARCOPENIA TREATMENT MARKET: MARKET END USERS COVERAGE GRID
FIGURE 8 NORTH AMERICA SARCOPENIA TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA SARCOPENIA TREATMENT MARKET: SEGMENTATION
FIGURE 10 THE RISING PREVALENCE OF SARCOPENIA AND GROWING AWARENESS OF SARCOEPNIA AND ITS DETRIMENTAL EFFECT ON HEALTH ARE EXPECTED TO DRIVE THE GROWTH OF THE NORTH AMERICA SARCOPENIA TREATMENT MARKET FROM 2023 TO 2030
FIGURE 11 VITAMIN/DIETARY SUPPLEMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA SARCOPENIA TREATMENT MARKET IN 2023 AND 2030
FIGURE 12 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA SARCOPENIA TREATMENT MARKET
FIGURE 13 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY TREATMENT TYPE, 2022
FIGURE 14 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY TREATMENT TYPE, 2023-2030 (USD THOUSAND)
FIGURE 15 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2023-2030)
FIGURE 16 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 17 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY TYPE, 2022
FIGURE 18 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY TYPE, 2023-2030 (USD THOUSAND)
FIGURE 19 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY TYPE, CAGR (2023-2030)
FIGURE 20 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 21 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY STAGES, 2022
FIGURE 22 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY STAGES, 2023-2030 (USD THOUSAND)
FIGURE 23 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY STAGES, CAGR (2023-2030)
FIGURE 24 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY STAGES, LIFELINE CURVE
FIGURE 25 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2022
FIGURE 26 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD THOUSAND)
FIGURE 27 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)
FIGURE 28 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 29 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY GENDER, 2022
FIGURE 30 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY GENDER, 2023-2030 (USD THOUSAND)
FIGURE 31 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY GENDER, CAGR (2023-2030)
FIGURE 32 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY GENDER, LIFELINE CURVE
FIGURE 33 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY END USER, 2022
FIGURE 34 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY END USER, 2023-2030 (USD THOUSAND)
FIGURE 35 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY END USER, CAGR (2023-2030)
FIGURE 36 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 37 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 38 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND)
FIGURE 39 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 40 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 41 NORTH AMERICA SARCOPENIA TREATMENT MARKET: SNAPSHOT (2022)
FIGURE 42 NORTH AMERICA SARCOPENIA TREATMENT MARKET: COMPANY SHARE 2022 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
